Cerivastatin: A review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia

Drugs

Volumn 60, Issue 5, 2000, Pages 1179-1206

  Plosker, Greg L ^a   Dunn, Christopher J ^a   Figgitt, David P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ATORVASTATIN; CERIVASTATIN; CIMETIDINE; CLOFIBRATE; COLESTYRAMINE; CYCLOSPORIN; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; FUROSEMIDE; GEMFIBROZIL; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; IMIPRAMINE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; MAGNESIUM HYDROXIDE; MEVINOLIN; NIFEDIPINE; OMEPRAZOLE; PRAVASTATIN; PROPRANOLOL; PROTON PUMP INHIBITOR; SALICYLIC ACID; SIMVASTATIN; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; WARFARIN;

ASTHENIA; CLINICAL TRIAL; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MUSCLE DISEASE; NONHUMAN; REVIEW; RHINOPHARYNGITIS;

EID: 0033663397     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060050-00011     Document Type: Review

References (119)

1. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
2. Control of lipid disorders in patients with atherosclerotic vascular disease
3. Management of hypercholesterolemia
4. Cerivastatin: Pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor
5. Cerivastatin: High enzyme affinity and active metabolites contribute to its high pharmacological activity
6. BAY W 6228: A new generation HMG-CoA reductase inhibitor. II. Inhibition of cholesterol synthesis in rats and dogs
7. Ascending multiple dose safety, tolerability and pharmacodynamics of rivastatin in humans
8. Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth
9. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes
10. Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures
11. Reduction of plasma cholesterol levels and inhibition of smooth muscle cell (SMC) proliferation by cerivastatin sodium, a new HMG-CoA reductase inhibitor [abstract]
12. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types
13. HMG-CoA reductase inhibitor-induced reduction of monocyte adhesion to vascular endothelium involves small GTP binding protein Rho dependent mechanism
14. HMG-CoA reductase inhibitors affect the fibrinolytic system of human vascular smooth muscle cells in vitro
15. Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits
16. Cerivastatin prevents the expression of urokinase and urokinase receptor on activated monocytes. A possible mechanism of protection against atherothrombosis
17. Rapid improvement of endothelial function after lipid-lowering therapy with cerivastatin within two weeks
18. Changes of serum steroid hormone levels in patients with type 2 diabetes after treatment with cerivastatin
19. Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation
20. Cerivastatin, an HMG-CoA reductase inhibitor, strongly inhibits human vascular smooth muscle cell growth: Effects on cell cycle regulators
21. Activation of mitogen activated protein kinases by monocyte chemoattractant protein-1 in human endothelial cells is suppressed by cerivastatin
22. New insights into plaque stabilisation by lipid lowering
23. Effects of calcium antagonism and HMG-coenzyme reductase inhibition on endothelial function and atherosclerosis: Rationale and outline of the ENCORE trials
24. Effects of the CSE-inhibitor cerivastatin on insulin sensitivity in insulin resistant first degree relatives of parents with type 2 diabetes mellitus - A placebo controlled study
25. Clinical pharmacokinetics of cerivastatin
26. Cerivastatin (BAY w 6228): A novel HMG-CoA reductase inhibitor
27. Biopharmaceutical profile of cerivastatin: A novel HMG-CoA reductase inhibitor
28. Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia
29. Pharmacokinetics of cerivastatin when administered under fasted and fed conditions in the morning or evening
30. Pharmacokinetics of cerivastatin administration with and without food in the morning and evening
31. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin
32. Preclinical review of cerivastatin sodium - A step forward in HMG-CoA reductase inhibition
33. Influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers
34. Pharmacokinetics, safety and tolerability of multiple-dose cerivastatin in males and females: A double-blind study [abstract]
35. Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin
36. Mild renal impairment does not alter the pharmacokinetics of cerivastatin in normocholesterolemic adults
37. Pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance
38. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions
39. Fluvastatin safety, efficacy and kinetics in the treatment of hypercholesterolemia in renal-transplant patients receiving cyclosporine
40. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients
41. Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations
42. Plasma concentration profiles of simvastatin 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin
43. Clinical pharmacokinetics of pravastatin
44. Pharmacokinetics of fluvastatin and specific drug interactions
45. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolaemia
46. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors
47. Clinical pharmacokinetics of 3hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors
48. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: Similarities and differences
49. 2-antagonist cimetidine on the pharmacokinetics of cerivastatin
50. The effect of omeprazole pre- and cotreatment on cerivastatin absorption and metabolism in man
51. Influence of cholestyramine on the pharmacokinetics of cerivastatin
52. Lack of pharmacokinetic drug-drug interaction between orlistat and cerivastatin
53. No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin
54. Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers
55. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin
56. Effect of itraconazole on cerivastatin pharmacokinetics
57. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin
58. Lack of drug-drug inter-action between cerivastatin and nifedipine
59. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients
60. Cerivastatin and atorvastatin: Efficacy, safety and drug-interaction of the new HMG-CoA reductase inhibitors in renal transplant recipients
61. Cerivastatin
62. Extending therapy options in treating lipid disorders: A clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor
63. Clinical efficacy and safety of cerivastatin: Summary of pivotal phase IIb/III studies
64. Effects of BAY w 6228 on serum lipid and apoprotein levels in patients with hypercholesterolemia in Japan
65. A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia
66. Cerivastatin, a new potent synthetic HMG Co-A reductase inhibitor: Effect of 0.2 mg daily in subjects with primary hypercholesterolemia
67. Efficacy and safety of cerivastatin 0.1 mg, 0.2 mg and 0.3 mg in Chinese patients with primary hypercholesterolaemia: A multicentre, randomised, doubleblind, placebo-controlled study
68. International multicentre comparison of cerivastatin with placebo and simvastatin for the treatment of patients with primary hypercholesterolaemia
69. Cerivastatin in the treatment of mixed hyperlipidemia: The RIGHT study
70. Comparison of the efficacy and safety of atorvastatin versus cerivastatin in patients with hypercholesterolemia
71. Cerivastatin, a new potent HMG-CoA reductase inhibitor: Efficacy and tolerability in primary hypercholesterolemia
72. Cerivastatin, a novel potent HMG-CoA reductase inhibitor: Comparative efficacy versus fluvastatin
73. Efficacy and safety of cerivastatin in primary hypercholesterolemia: A long term comparative titration study with simvastatin
74. Efficacy and safety of cerivastatin and pravastatin in the treatment of patients with primary hypercholesterolemia
75. Clinical efficacy of cerivastatin: Phase IIa dose-ranging and dose-scheduling studies
76. A pooled efficacy analysis of cerivastatin in the treatment of primary hyperlipidaemia
77. Long-term safety and efficacy of cerivastatin, a potent new HMG-CoA reductase inhibitor effective at ultra-low doses
78. Efficacy and safety of 300 μg and 400 μg cerivastatin once daily in patients with primary hypercholesterolaemia: A multicentre, randomized, double-blind, placebo-controlled study
79. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: The pivotal placebo-controlled clinical trial
80. Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: A multinational, randomised, double-blind study
81. The 0.4 mg dose of cerivastatin: Comparative safety and efficacy of cerivastatin 0.3 mg versus fluvastatin 40 mg [abstract]
82. Efficacy and safety of cerivastatin 0.8 mg versus pravastatin 40 mg for treatment of dyslipidaemia
83. Long-term (52 week) efficacy and safety of cerivastatin 0.8 mg and 0.4 mg vs. pravastatin 40 mg
84. Improved NCEP-goal attainment with cerivastatin: Outcome of mandated department of defense statin conversion
85. Efficacy and safety of a formulary statin conversion program: Prospective validation of the Department of Defense pharmacoeconomic center guidelines
86. Equivalent efficacy and safety of cerivastatin and simvastatin: Outcome of mandated statin conversion program at the Cleveland VA medical center
87. Cerivastatin gender effect: Sub-analyses of results from a multinational, randomised, double-blind study
88. Efficacy and safety of cerivastatin for type 2 diabetes and hypercholesterolaemia
89. Lipids in diabetes study
90. Efficacy and safety of cerivastatin/bezafibrate combination therapy for dyslipidaemia
91. Efficacy and safety of cerivastatin/fenofibrate combination therapy for hypercholesterolemia
92. Clinical efficacy and safety of cerivastatin in the treatment of heterozygous familial hypercholesterolemia
93. HMG-CoA reductase inhibitors and myotoxicity
94. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil
95. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy
96. Cerivastatin-induced rhabdomyolysis
97. Prevalence of high blood cholesterol among U.S. adults: An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel
98. Epidemiology of hypercholesterolemia and European management guidelines
99. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
100. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
101. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
102. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a board range of initial cholesterol levels
103. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
104. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
105. Risk evaluation and stroke prevention in the elderly - Cerivastatin trial (RESPECT)
106. Prevention of coronany heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
107. Drug treatment of lipid disorders
108. The Lipid Treatment Assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
109. Cost effectiveness of coronary heart disease prevention strategies in adults
110. Cholesterol-lowering therapy interventions: A pharmacoeconomic assessment
111. Maximizing the cost-effectiveness of lipid-lowering therapy
112. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction
113. Impact of new statin doses on market segmentation
114. Economic segmentation of statins: Price versus efficiency
115. Cost-effectiveness analysis for statin therapies in the primary prevention of coronary heart disease in Italy